. Author manuscript; available in PMC: 2016 Dec 7.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Mar 24;15(6):323–334. doi: 10.1016/j.clml.2015.03.006

Table 3.

Cytogenetic Response as an Independent Predictor of Clinical Outcomes in CML Patients Receiving TKIs Post–Imatinib Failure

Reference	Patient Population	TKI Therapy	Predictive Factor (Time Frame)	Outcomes
Reference	Patient Population	TKI Therapy	Predictive Factor (Time Frame)	EFS	OS
Tam et al 2008⁴⁹	N=113 CP-CML (n=87) AP-CML (n=26)	Nilotinib (n=43) or dasatinib (n=70)	MCyR vs MiCyR or CHR (by 1 y)	At 2 y: probability of progression 3% (with 1-y MCyR) vs 17% (with 1-y MiCyR or CHR), P=0.003	At 2 y: 97% (with 1-y MCyR) vs 84% (with 1-y MiCyR or CHR), P=0.02
Jabbour et al 2011⁵⁰	CP-CML (N=123)	Nilotinib (n=45) or dasatinib (n=78)	MCyR vs no MCyR (at 1 y)	After median follow-up of 38 mo: lack of 1-y MCyR adverse factor for EFS; HR=2.3, P<0.001	NR
Jabbour et al 2013⁵¹	CP-CML (N=123)	Nilotinib (n=45) or dasatinib (n=78)	CCyR vs no CCyR (at 3 mo)	At 3 y: 74% (with 3-mo CCyR) vs 43% (without 3-mo CCyR), P=0.002; multivariate analysis: HR=4.5 (95% CI, 2.12–11.66), P<0.01	At 3 y: 98% (with 3-mo CCyR) vs 79% (without 3-mo CCyR), P=0.005; multivariate analysis: HR=5.4 (95% CI, 1.27–10.87), P=0.03

Abbreviations: AP = accelerated phase; CCyR = complete cytogenetic response; CHR = complete hematologic response; CI = confidence interval; CML = chronic myeloid leukemia; CP = chronic phase; EFS = event-free survival; HR = hazard ratio; MCyR = major cytogenetic response; MiCyR = minor cytogenetic response; NR = not reported; OS = overall survival; TKI = tyrosine kinase inhibitor.